NIH R01 · 2025
ABSTRACT Clostridioides difficile (Cd) infection (CDI) is a leading cause of healthcare-associated infections in the U.S., affecting ~500,000 people and costing ~$5.4B annually. Despite substantial advances in investigating Cd pathogenesis and transmission over the past 20 years, CDI remains a significant public health burden. Conventional antimicrobial therapy often fails to clear Cd, can inflict extensive collateral damage to the commensal gut microbiome (GM), and frequently leads to recurrent CDI, for which treatment options are limited. A major impediment in mitigating Cd-associated disease is current unclear understanding of the biological basis for the broad spectrum of disease…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.